ArticleACS omega2025
Synthesis, Characterization, and Dual Functional Properties of Coumarin-Based Hybrids for Biological and Optical Applications.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Coumarin-Based Hybrids: From Linear Photophysical Properties to Multiphoton Excitation Behavior.ACS physical chemistry Au · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterocyclic compounds incorporating nuclei of coumarin, benzimidazole, and benzothiazole exhibit significant biological and pharmacological properties. This study presents an efficient synthetic route for hybrid molecules integrating coumarin with either benzimidazole or benzothiazole under mild reaction conditions. The antibacterial and antioxidant properties of the synthesized compounds were systematically evaluated. The methodology successfully yielded 11 compounds in total, including six substituted coumarin-benzimidazole and five coumarin-benzothiazole derivatives, with yields ranging from 14 to 60%. Notably, derivatives
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.